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Bcl-2Apoptosis is an elemental form of programmed cell death; it is fundamental to higher eukaryotes and
essential to mechanisms controlling tissue homeostasis. Apoptosis is also involved in many pathologies
including cancer, neurodegenerative diseases, aging, and infarcts. This cell death program is tightly regulated
by Bcl-2 family proteins by controlling the formation of the mitochondrial apoptosis-induced channel or
MAC. Assembly of MAC corresponds to permeabilization of the mitochondrial outer membrane, which is the
so called commitment step of apoptosis. MAC provides the pathway through the mitochondrial outer
membrane for the release of cytochrome c and other pro-apoptotic factors from the intermembrane space.
While overexpression of anti-apoptotic Bcl-2 eliminates MAC activity, oligomers of the pro-apoptotic
members Bax and/or Bak are essential structural component(s) of MAC. Assembly of MAC from Bax or Bak
was monitored in real time by directly patch-clamping mitochondria with micropipettes containing the
sentinel tBid, a direct activator of Bax and Bak. Herein, a variety of high afﬁnity inhibitors of MAC (iMAC) that
may prove to be crucial tools in mechanistic studies have recently been identiﬁed. This review focuses on
characterization of MAC activity, its regulation by Bcl-2 family proteins, and a discussion of how MAC can be
pharmacologically turned on or off depending on the pathology to be treated., 345 East 24th St., New York
USA. Tel.: +1 212 998 9445;
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Normal development and tissue homeostasis in multi-cellular
organisms rely on the conserved cell death mechanism of apoptosis
(reviewed in [1–4]). There are two principal signaling cascades leading
to cell death by apoptosis. They are the extrinsic or death receptor
pathway and the intrinsic or mitochondrial pathway. The extrinsic
pathway is turned on in response to extracellular signals and involves
activation of plasma membrane receptors through binding of ligands
like Fas/CD95, TNFα and TRAIL [5]. Receptor activation ultimately leads
to processes that trigger initiator caspases, like caspase 8 and 10, which
in turn activate executioner caspases, like caspase 3 and 7. Executioner
caspases orchestrate the appearance of late apoptosis markers such as
DNA fragmentation and blebbing of the plasma membrane.
Mitochondria are central players in the intrinsic pathway of
apoptosis, which is turned on in response to a diverse set of apoptotic
signals, including DNA damage, growth factor withdrawal, and viral
infection. Mitochondria release a number of cofactors from their
intermembrane space, like cytochrome c, Smac/Diablo, and AIF, which
promote and amplify the apoptotic cascade from the formation and
activation of the apoptosomes to the ﬁnal destruction of the cell [1,3,6–10]. The Bcl-2 family of proteins is a key regulator of the mitochondrial
response to apoptotic signals and contains both pro- and anti-apoptotic
members. Many of these proteins localize to mitochondria and ﬁnely
control apoptosis through regulation of the release of these cofactors
from mitochondria (reviewed in [3,11]). The extrinsic and intrinsic
pathways initially appeared to be independent. However, it is now clear
that a crosstalk exists between the twopathways that ismediatedby the
sentinel or ‘BH3 only’ proteins like Bid [12]. For example, caspase 8 is
activated in early extrinsic apoptosis and directly turns on the
executioner caspase 3. However, caspase 8 also cleaves Bid to form
tBid, which facilitates cytochrome c release and enables the cell to
mount a more robust apoptotic response. Thus, tBid is generated by the
extrinsic pathway and crosses over to activate the intrinsic pathway.
The mechanisms underlying release of pro-apoptotic factors from
mitochondria remain a subject of lively debate. This release was
attributed to the opening of the permeability transition pore (PTP) in
the mitochondrial inner membrane several years ago. Sustained PTP
opening causes swelling of the matrix space and bursting of the outer
membrane. This rupture of the outer membrane would spill
cytochrome c and other intermembrane space proteins into the
cytosol. However, this scenario may not normally occur in early
apoptosis. Instead, sustained PTP opening is now thought to play a
central role in ischemia–reperfusion injury and necrosis [13–15]. The
role of PTP in apoptosis may be indirect. Brieﬂy, cyclophilin-D is the
target of cyclosporine A and a regulator of the PTP. Surprisingly,
cyclophilin-D deﬁcient cells died normally in response to apoptotic
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contrast, these KO cells showed resistance to necrotic cell death
induced by either reactive oxygen species or Ca2+ overload [13].
Perhaps the “nail in the cofﬁn” for PTP playing a role in apoptosis was
the observation that cytochrome c release occurred in the absence of
mitochondrial depolarization and without loss of outer membrane
integrity. These observations indicate that, instead of rupturing, a
more selective mechanism of permeabilization is operating, like the
formation of a pore in the outer membrane [16–21].
Directly patch-clamping mitochondria isolated from apoptotic
cells enabled identiﬁcation of the mitochondrial apoptosis-induced
channel or MAC. This channel activity is not present in mitochondria
of normal cells and is exquisitely regulated by Bcl-2 family proteins.
Several observations strongly indicate that MAC provides the aqueous
pathway through the mitochondrial outer membrane requisite for the
release of pro-apoptotic factors like cytochrome c [17,20,21].
Nevertheless, MAC and PTP opening may act alone or in combination,
depending on cell type and death stimulus, to remodel the cristae, and
facilitate cytochrome c release during ampliﬁcation of the death
signal [19,22]. The two focuses of this review are the regulation of
MAC by Bcl-2 family proteins and how MAC can be a potential
therapeutic target in cancer and degenerative diseases.
2. What is MAC?
MAC is a channel with a giant pore, big enough to allow passage of
proteins with diameters >3 nm, like cytochrome c. This channel
activity was ﬁrst detected by directly patch-clamping mitochondria
isolated from FL5.12 cells, 12h after withdrawal of interleukin-3 (IL-3)
to induce apoptosis [17]. MAC can also be studied after reconstitution
in proteoliposomes formed with mitochondrial outer membranes
puriﬁed fromapoptotic cells.Membranepatches are removed from the
proteoliposomes with a micropipette and the ionic current through
individual channels is characterized.
MAC is a channel whose conductance is both large and hetero-
geneous, but is generally between 2.5 and 5 nS [17,20,21]. Functional
MAC has a peak conductance of >1 nS and displays transitions of up to
~2 nS with multiple sub-conductance levels in 150 mM KCl (Fig. 1,
Table 1). While ﬂickering between substates is observed, current
traces often show MAC occupying a stable fully open state with
relatively infrequent transitions [17,20,21]. The activity of MAC is
signiﬁcantly different from TOM and VDAC, which are constitutive
channels of the mitochondrial outer membrane. The single channel
parameters of peak conductance, transition size, selectivity, and
voltage dependence for these channels are shown in Table 1.
MAC is typically a voltage-independent channel [17,20,21,23],
although it has also been reported to occupy less than peak conduc-
tances at higher potentials [24]. The channel is slightly cation-selective,
which is consistent with MAC's putative role in releasing the cationic
protein cytochrome c. The polymer exclusion method was used to
estimate thepore sizeofMAC [20], ashas beendonewith other channels
[25–30]. These studies indicate that MAC with a conductance of 4 nS is
permeable to 10 and 17 kDa, but not 45 and 71 kDa Dextran. The
polymer exclusion experiments suggest that 1.5 to 5 nSMAC have pore
diameters in the range of 2.9 to 7.6 nm.
3. MAC is the cytochrome c release channel
MAC provides the pathway through the outer membrane for
release of cytochrome c early in apoptosis and this notion is supported
by a variety of observations. In patch clamp experiments, cytochrome
c modiﬁes the behavior of MAC in a manner consistent with its
entrance into the pore, which is an essential step of translocation
[20,21]. Physiological concentrations (0.1–1 mM) of cytochrome c
reduced MAC conductance with increased channel noise in a voltage
dependent manner [20,31]. The pore size of MAC estimated asmentioned above is sufﬁcient to allow the passage of 12.5 kDa
cytochrome c. In addition, the onset of MAC activity coincides with
cytochrome c release in several systems [17,20,21,23,32,33]. The
temporal association of MAC formation and cytochrome c release is
consistent with biochemical ﬁndings. Speciﬁcally, MAC conductance
is found in mitochondria isolated from apoptotic cells at the same
time that Bax is translocated to the outer membrane and cytochrome
c was released [21]. Also, proteoliposomes made from apoptotic
membranes express MAC activity and fail to retain cytochrome c
compared with those prepared from control cells [17]. Hence,
cytochrome c permeability increases early in apoptosis when MAC
activity is present. Finally, the multitude of effects of Bcl-2 family
proteins on this activity described below also strongly support MAC's
identiﬁcation as the cytochrome c release channel.
4. Balance within the Bcl-2 family of proteins
The Bcl-2 family of proteins is the fundamental regulator of
mitochondrial apoptosis. As shown in Table 2, proteins in this family
contain between one and four Bcl-2 homology (BH) domains. These
α-helical domains allow the Bcl-2 family proteins to form hetero-
dimers by interacting with each other, a process that is central to the
mechanism by which they regulate apoptosis. There are three main
functional groups of proteins in this family. The anti-apoptotic
proteins contain four BH domains (BH1 to BH4). The BH1, BH2 and
BH3 domains form a hydrophobic cleft that binds the hydrophobic
face of BH3 domains of pro-apoptotic proteins. Themulti-domain pro-
apoptotic proteins have the BH1, BH2, and BH3 domains, but lack a
BH4 domain. The pro-apoptotic sentinels, or BH3-only proteins, share
only a BH3 domainwith the rest of the Bcl-2 family. BH3-only proteins
are also subdivided into direct activators and sensitizers and whether
PUMA is a sensitizer or direct activator remains a subject of debate
(Table 2).
Many Bcl-2 family proteins eventually localize to mitochondria
and ﬁnely control the process of releasing apoptosis mediators into
the cytosol (recently reviewed in [1,3,8,10]). Some translocate upon
apoptotic signaling like Bcl-xL and Bax, while others, like Bcl-2 and
Bak, are resident proteins in the outer membrane and contact sites
[34]. The pro-apoptotic multi-domain proteins like Bax are essential
to the machinery underlying permeabilization of the outer membrane
and, as described below, are structural components of MAC. On the
other hand, anti-apoptotic members such as Bcl-2, inhibit this
process by directly binding to and sequestering the pro-apoptotic
effector proteins [11]. Finally, the sentinels are pro-apoptotic proteins
that relay the apoptotic signal to mitochondria by interacting with
pro- (direct activators) or anti- (sensitizers) apoptotic Bcl-2 family
proteins [1,3,11]. Members of each of these classes have effects on
MAC formation and activity as shown in Table 2. Importantly, the
combined signaling through protein–protein interactions of the
various types of Bcl-2 family proteins controls the immediate fate of
the cell, i.e., the decision to or not to induce permeabilization of the
outer membrane when challenged with apoptotic stimuli [3]. Finally,
mounting evidence indicates that this permeabilization phenomenon
occurs through formation of the cytochrome c release channel MAC
(see [8,10,35] for reviews).
5. MAC activity is tightly linked to Bax and Bak
Previous studies using single and double knock out cell lines for
Bax and Bak found that these two proteins are functionally redundant
with respect to their role in apoptosis (see [36–39] for reviews).
Patch-clamp studies of mitochondria isolated from cells deﬁcient in
one or both Bax and Bak show that at least one of the proteins must be
present for formation of MAC [32]. Fig. 1 shows cytochrome c release
and an increase in mitochondrial permeability corresponding to MAC
assembly, is recorded in mitochondria containing Bax and/or Bak, but
Fig. 1.MAC and rBax channel formation. A, B. Mitochondria were isolated from Parental, Bax KO, Bak KO and DKO (Double Knockout) MEF cell lines as indicated 16h after apoptosis
was induced by 1 µM staurosporine (STS). A. The peak conductances of outer membranes were measured by directly patch clamping mitochondria isolated from control and
STS-treated MEF cells. Histograms show the increase in conductance corresponding to the difference between the mean conductance of STS-treated and control patches. These
permeability increases were consistent with the presence of MAC in mitochondria of apoptotic Parental, Bax KO and Bak KO cells, but not in the STS-treated DKO cells. Data were
mean of 20–23 independent patches, error bars indicate SE. B. Histograms show the cytochrome c release to the cytosol monitored by ELISA and expressed relative to the positive
control alamethicin (80 µg/106 cells). Data were mean±SE of at least 3 different preparations. C. Current traces are shown of the formation of MAC and recombinant Bax (rBax)
channels. Amitochondrion isolated from healthy parental MEF cells was patch-clamped with a micropipette containing 20 nM tBid. Time indicated was since seal formation. Current
trace labeled rBax was from a liposome patch that showed an increase in conductance with time when 380 ng/μl of monomeric BaxΔC and 35 ng/μl tBid were included in the
micropipette. The conductance increased in multiple steps of ~300 pS until it reached about 1200 pS.
Modiﬁed from ref. [32].
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indicated in Table 1, although some differences were detected, the
single channel behaviors of MACs containing exclusively Bax or Bak
are similar [32]. Considering Bax was shown to be a component of
MAC [21], these data support the notion that Bak may replace Bax as a
structural component of MAC in cells deﬁcient in Bax. That is, Bax and
Bak are functionally redundant with respect to MAC.
Other studies determined that it is oligomeric, not monomeric, Bax
that contributes to MAC activity. Bax is a component of MAC of
staurosporine-treated HeLa cells because MAC activity is depleted after
immunoprecipitation of oligomeric Bax. In this system, MAC activity isTable 1
Electrophysiological properties of MAC containing Bax and/or Bak, VDAC and TOM channe
Parental Bax KO
Peak conductance (nS) 3.5±1.8 (n=7) 3.1±2.0 (n=8)
Transition size (nS) Up to 2 Up to 2
Ion selectivity PK+/PCl– 3.1±1.4 (n=5) 3.7 (n=1)
Voltage dependent (±50 mV) No No
Predicted diameter (nm) 6 5.6
Predicted # helices forming Pore 18 17
[tBid] EC50 (nM) cyt. c release 7 17
a Measurements were made in 150 mM KCl containing buffer. n. a. stands for not applica
artiﬁcial membranes [17,21]. Diameters of MAC and number of helices were calculated frompresent in total mitochondrial lysates and fractions containing oligo-
meric, but not monomeric, Bax [21]. This is expected as Bax oligomers
form in the outer membrane following Bax translocation to mitochon-
dria at the time that cytochrome c is released [19,21,40,41]. Importantly,
MACactivity is depleted from solubilizedmitochondrial fractions byBax
antibodies raised against an N-terminal epitope of the protein [21]. This
epitope is inaccessible in monomeric Bax but becomes exposed
following Bax activation. Thus, these antibodies selectively immuno-
precipitate oligomeric Bax [42,43]. The concomitant loss ofMAC activity
and oligomeric Bax by immunoprecipitation provides strong evidence
that activated/oligomeric Bax is a component of MAC.lsa.
Bak KO rBax VDAC TOM
3.0±1.9 (n=8) 5.0±3.0 0.7±0.1 0.7±0.1
Up to 2 Up to 2 0.35 0.35
3.4±1.2 (n=4) 6.8±1.0 0.5 3.6±0.8
No No Yes Yes
5.5 5.1±1.7 2.0±0.2 2.0±0.1
17 22 n. a. n. a.
247 n. a. n. a. n. a.
ble. n=number of determinations. rBax, recombinant oligomeric BaxΔC20 channels in
conductances as previously described [17,32]. VDAC selectivity was from ref. [81].
Table 2
The Bcl-2 family of proteins is divided into three functional groups based on their composition of BH domainsa.
Class Subclass Members Domains Normal function Role in MAC regulation
Anti-apoptotic
Effectors (AE)
Multi-domain Bcl-2, Bcl-xL, Mcl-1,
Bcl-w, A1 (Bﬂ-1)
BH1–4 Inhibit PEs & sentinels at MOM
through direct interaction [3,10]
-Bcl-2 inhibits MAC formation [17]
-Bcl-xL inhibits MAC-like activity in
yeast expressing Bax [17]
Pro-apoptotic
Effectors (PE)
Multi-domain Bax, Bak, Bok BH1–3 Permeabilize MOM during apoptosis [3,10] -Bax is a MAC component [21]




Direct Activators Bid, Bim, p53, PUMA? BH3 Relay pro-apoptotic signal by interacting
with PEs [3,10]
-tBid induces MAC formation in either
Bax−/− or Bak−/− mitochondria [21,32]
Sensitizers Bad, NOXA, Hrk, PUMA? BH3 Relay pro-apoptotic signal by interacting
with AEs [3,10]
-n. d.
a BH: Bcl-2 Homology domains; n. d. stands for not determined.
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variety of data. While Bax monomers form channels, the conductance
corresponds to a pore that is likely too small to allow passage of
cytochrome c [44,45]. However, non-selective, voltage-independent
channels that show a gradual increase in conductance up to 5.4 nS
form if Bax is oligomerized prior to insertion into planar bilayers [46].
The diameter estimated from the peak conductance of 5.4 nS for rBax
channels is >5 nm, which should easily allow the passage of ~3 nm
cytochrome c [47]. This discovery was conﬁrmed in a study in which
the channel forming activity of oligomeric Bax was monitored by
patch-clamp techniques (Fig. 1, Table 1) [21]. Cytochrome c and
RNAse A have the same effects on MAC and recombinant BaxΔC20
channels, while hemoglobin has no effect. Similarly, heterologous
expression of Bax induces cell death and cytochrome c release in yeast
[48,49]. Using this system, we found expression of c-myc tagged
human Bax (hBax) induced a MAC-like activity in yeast mitochondria.
Patch-clamping yeast mitochondria expressing hBax in a VDAC-less
strain detected a novel channel activity, which again, was similar to
MAC activity found in apoptotic mammalian mitochondria [17,21].
Furthermore, MAC activity appears when Bax levels increase in
mitochondria of apoptotic FL5.12 cells [17]. MAC is also detected as an
increase in outer membrane permeability by patch-clamp techniques
in staurosporine-treated HeLa cells at the time Bax-GFP forms clusters
in mitochondria and cytochrome c is released [21]. While correlative,
this evidence supports the mechanistic link between Bax transloca-
tion and oligomerization, MAC formation, and cytochrome c release
that was directly tested by the molecular and immunological studies
described above.
6. Regulation of MAC by the sentinel or BH3-only proteins
The BH3-only proteins are the sentinels that translate the survival
and apoptotic signals emanating from throughout the cell. There are
two functional classes of sentinels; they are direct activators or
sensitizers (Table 2). Bid, Bim, p53, and perhaps PUMA directly
interact with the multi-domain pro-apoptotic Bax and Bak to cause a
conformational change, which presumably triggers their oligomeri-
zation leading to MAC formation [3,50]. Bad, NOXA, and perhaps
PUMA are sensitizers which bind the hydrophobic pocket of the anti-
apoptotic proteins like Bcl-2 to displace the normally sequestered
direct activators, like Bim, or even possibly the pro-apoptotic effectors
Bax and Bak [3,50]. The elevation in liberated pro-apoptotic proteins
shifts the balance within the family towards apoptosis. Nevertheless,
Bax and Bak presumably remain inert until a direct activator sentinel
induces the conformational change that allows their oligomerization.
Yet another layer of regulation exists within the BH3-only group. For
example, Bad must be dephosphorylated while Bid needs to be
cleaved in order to assume their sentinel status as sensitizers and
direct activators, respectively [51,52].
During apoptosis, inactive Bid is cleaved to form a C-terminal
truncated form referred to as tBid, which functions as a directactivator. The fragment tBid triggers oligomerization of both Bax and
Bak in the mitochondrial outer membrane presumably to form MAC,
which causes cytochrome c release (Fig. 2 left) [53,54]. Furthermore,
tBid can trigger oligomerization of recombinant monomeric Bax in
artiﬁcial membranes [21,46]. The oligomerization results in formation
of voltage independent and slightly cationic channels with conduc-
tances of up to several nS, which are detected by patch-clamp
techniques (Fig. 1, Table 1) [21]. Moreover, cytochrome c is
transported through these tBid induced Bax channels, which again
makes them very similar to MAC [21].
We used tBid to induce MAC activity in mitochondria in order to
visualize formation of the pore of MAC in real time [32]. As shown in
Fig. 1, a large conductance developed with time when control
mitochondria were patch-clamped with micropipettes containing
tBid [32]. Nanomolar levels of tBid catalyzed MAC formation and
cytochrome c release with a time course of minutes. Interestingly, the
amount of tBid needed to form MAC and release cytochrome c in
mitochondria lacking Bax and/or Bak was different. MAC formed from
Bak with an EC50 of about 20 nM tBid but MAC needed >200 nM tBid
to form from Bax [32]. It is not known if this was due to differences in
available Bax or Bak in these mitochondria. As expected, MAC did not
form in mitochondria lacking both Bax and Bak.
Mathematical analysis of the step-wise changes in conductance
associated with tBid and MAC formation was consistent with pore
assembly by a barrel-stave model. Assuming the staves are two
transmembrane α-helices in Bax and Bak, mature MAC pores would
typically contain ~9 monomers and have diameters of 5.5–6 nm. The
role of other sentinel proteins like Bad and Bim onMAC formation and
activity is still under investigation. However, there are reports that
lipids may also play a central role in cytochrome c release. For
example, the lipid ceramide forms channels in mitochondrial outer
membranes that are in part regulated by Bcl-2 family proteins and the
channels formed from Bax and peptides mimicking regions of Bax
may indeed form lipidic pores [55–57]. Hence, the assembly
mechanism of MAC is not yet resolved.
7. Regulation of MAC by the anti-apoptotic proteins
Bcl-2 is one of the best studied anti-apoptotic proteins in the Bcl-2
family (Table 2) [36–39,55]. However, several other members of this
subclass co-exist with Bcl-2 within the cell as shown in Table 2. Some
differences exist in their abilities to bind other members to form
heterodimers. Bcl-2 and Bcl-xL seem to bind almost all the pro-
apoptotic members. A hydrophobic cleft is formed by the BH1, BH2
and BH3 domains of anti-apoptotic proteins that provides a binding
site for the hydrophobic face of BH3 domains of pro-apoptotic
proteins. Presumably, it is at this site that Bcl-2 and Bcl-xL inhibit
apoptosis by sequestering Bax, Bak and direct activator sentinels like
Bim. Interestingly, Mcl-1 is the only member that binds the sentinel
NOXA and Bcl-xL is the only one that binds Hrk [7,58]. As described
below (Fig. 2), the inhibitors of anti-apoptotic action, like ABT-737,
Fig. 2. MAC formation in mitochondria from normal and Bcl-2-overexpressing cells. Left: Upon apoptotic stimulus, the sentinel Bim ( ) translocates to mitochondrial outer membrane
(mom) where it catalyzes Bax ( ) activation and conversion of MAC precursors into functional MAC. MAC releases cytochrome c ( , cyt c) from the intermembrane space (ims) in the
commitment step to death. As yet unidentiﬁed interacting proteins ( ) are also shown. iMACs block the release of cytochrome c and death by inhibiting MAC. Center: In cells
overexpressing Bcl-2 ( ), an apoptotic signal induces accumulation of Bim/Bcl-2 complexes, butMAC is still in its precursor form and cytochrome c is not released. Accumulation of Bim/
Bcl2-containing complexes represents the putativemechanism bywhich Bcl-2 overexpression primes cells to die. Right: Addition of ABT-737 disrupts Bcl-2 complexes with Bax and Bim
to allow MAC formation and cytochrome c release. Bax, Bim, and Bcl-2 represent a pro-apoptotic effector, a sentinel and an anti-apoptotic effector protein, respectively.
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and unlike most anti-apoptotic proteins, the action of Mcl-1 is not
inhibited by ABT-737.
As expected, an excess of anti-apoptotic proteins blocks apoptosis
by preventing outer membrane permeabilization. MAC has never
been detected in IL-3 deprived FL5.12 cells that overexpress Bcl-2.
Furthermore, overexpression of Bcl-xL eliminated theMAC-like activity
of mitochondria from yeast expressing hBax [17]. These results suggest
that these anti-apoptotic proteins inhibit MAC formation. However,
the molecular mechanisms of this inhibition are, as yet, poorly deﬁned.
For example, does Bcl-2 block Bax translocation, activation, or just
oligomerization?
Recombinant Bcl-2 can form channels in planar bilayers [45,59]. In
contrast, no new channel activities are detected when Bcl-2 is
overexpressed in FL5.12 or MDA-231 cells, suggesting this protein
does not form channels in native mitochondrial membranes [17,60].
However, channels whose conductances are between 0.75 and 1 nS
are detected in isolatedmitochondria after addition of caspase cleaved
recombinant Bcl-xL (ΔN-Bcl-xL) [61]. These channels have conduc-
tances and other properties similar to mitochondrial channels
detected in squid giant synapses during early stages of hypoxia-
mediated apoptosis, when Bcl-xL is cleaved by caspases [62,63]. In
particular, conductances of up to 3.8 nS were detected in media
containing 570 mM KCl in the micropipette. For purposes of
comparison, this peak conductance should correspond to about 1 nS
in symmetrical 150 mM KCl. Hence, the pore size may be too small to
allow for cytochrome c transport and therefore these channels are
unlikely to have the same role as MAC during early apoptosis.
Importantly, the anti-apoptotic proteins like Bcl-2 cause an
accumulation of sentinel proteins, like Bim, in mitochondria [64].
While overexpression of Bcl-2 suppresses apoptosis, the excess of
sentinel proteins may be an Achilles' heel that might be exploited to
selectively target cancer cells to die.8. Antagonists and Agonists of MAC or the pharmacology of
cell death
MAC is a potential therapeutic target because of its role in the
commitment step of apoptosis, i.e., cytochrome c release. Hence, we
have striven to expand the pharmacological proﬁle of MAC so that thischannel can be turned on or turned off depending on the pathological
condition being treated.
It has been previously shown that triﬂuoperazine and propranolol
prevent apoptosis in some cell lines [65,66], and triﬂuoperazine and
dibucaine also block mitochondrial depolarization induced by
glutamate in neurons [67]. Dibucaine, triﬂuoperazine and propranolol
also block cytochrome c release from mitochondria induced by
recombinant Bax and BH3-only proteins like tBid [68]. We found
using patch-clamping that dibucaine, propranolol and triﬂuoperazine
inhibited MAC in a dose-dependent manner. The IC50 are 39 µM,
52 µM and 1 µM for dibucaine, propranolol and triﬂuoperazine,
respectively [23]. In contrast, lidocaine, a structural homolog of
dibucaine, and cyclosporine A, a well known PTP blocker [69–71], had
no effect on MAC activity [23]. Dibucaine, triﬂuoperazine and
propranolol also block cytochrome c release from mitochondria
induced by recombinant Bax and BH3-only proteins like tBid [68].
Hence, these studies provide yet another link between Bax and MAC.
However, each of these agents has low potency and pleiotropic effects.
Previously, Antonsson et al. identiﬁed two novel agents that block
the channel activity of recombinant Bax in planar bilayers and inhibit
release of cytochrome c induced by tBid [72]. Hence, these two agents
were named Bax channel inhibitors or Bci1 and Bci2. Furthermore,
Bci1 and Bci2 block apoptosis of neurons in an animal model of global
brain ischemia. Antonsson's group also identiﬁed 3,6 dibromocarba-
zole piperazine derivatives of 2-propanol that blocked cytochrome c
release induced by tBid in isolated mitochondria; some have IC50
values in the nM range [73]. As described below, we later named these
compound inhibitors of MAC (iMAC). We tested Bci1, Bci2, and
several potential iMACs for their ability to block MAC, and began an
assessment of their effects on apoptosis. Several of these agents were
effective in closing MAC in patch-clamp experiments at nM
concentrations (Table 3) [74]. As shown in Fig. 3, 25 nM iMAC2
rapidly closed MAC. The effects of iMAC2 showed speciﬁcity for MAC
as 500 nM iMAC2 had no effect on the activity of TOM, a constitutive
channel of the outer membrane. In all, ﬁve iMACs and the two Bci
compounds were tested and their IC50 values in patch-clamp
experiments are listed in Table 3 [74]. The toxicity of these
compounds was also determined. Importantly, the ratios of LD50
over IC50 values for Bci1, iMAC1, iMAC2 and iMAC3 were over 200,
which also suggest that these pharmacological agents have wide
therapeutic windows.
Table 3
Potency and toxicity of agents that block MAC.








Fig. 3. Effect of iMAC2 on MAC and TOM channels. MAC and TOM activities were
recorded in patches excised from reconstituted mitochondrial outer membranes of
apoptotic FL5.12 cells. Representative current traces at +20 mV of MAC and TOM
channels upon perfusion with buffer containing 25 nM and 500 nM iMAC2, respec-
tively. The current trace of TOM in the presence of iMAC2 was recorded ~1 min after
perfusion. Dashed lines indicate 0 current levels.
Modiﬁed from ref. [74].
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through the variation of the expression level of various members,
likely underlies some degenerative diseases and is known to cause
cancer. But, these imbalances may also reveal selective therapeutic
targets. For example, genetic events leading to overexpression of the
Bcl-2 proto-oncogene suppress apoptosis and are associated with
tumor formation and, more particularly, B-Cell non-Hodgkin's
lymphoma [75–77]. Prolymphocytic cell lines overexpressing Bcl-2
exhibit a resistance to mitochondrial apoptosis and induce lymphoma
upon injection in mice [17,33,75,78]. Hence, overexpression of Bcl-2 is
associated with cancer. While these cells are more resistant to death,
apoptotic stimuli cause the sequestration of sentinel proteins such as
Bim in mitochondria [64,79]. This accumulation has been coined
sensitization or “primed to die” and is illustrated in Fig. 2. Small
molecules that mimic the important BH3 domain can function as
competitive inhibitors and bind to the hydrophobic cleft in Bcl-2. In
doing so, these BH3 mimetics release sequestered pro-apoptotic
proteins and the primed cells now die. Like most apoptotic stimuli,
BH3-mimetics alone often do not kill these cells. However, the
BH3-mimetics may act synergistically with chemotherapeutic agents
(which provide the apoptotic signal) to trigger an increase in MAC
formation and selectively kill cancer cells overexpressing anti-
apoptotic proteins like Bcl-2. That is, BH3 mimetics, represented by
ABT-737 in Fig. 2, are able to selectively kill these cancer cells by
inhibiting the interactions e.g., between Bcl-2 and Bim [50,58,64] and
triggering an increase of MAC formation (Fig. 2), a propertypotentially optimized by the activity of direct MAC activators which
are yet to be found. It is important to note that ABT-737 inhibits all the
known anti-apoptotic proteins except Mcl-1. Naturally, this “priming
for death” approach will only work on cancer cells whose survival
relies on overexpression of anti-apoptotic proteins and accumulation
of pro-apoptotic proteins in mitochondria. Hence, development of
personalized chemotherapy using BH3 mimetics will likely require
pre-diagnosis of such an anti-apoptotic addiction through BH3
proﬁling [50,58,64].
9. Future perspectives
MAC is central to the commitment step of apoptosis and a
potential therapeutic target. Turning MAC on should induce cell death
and turning MAC off should suppress cell death. Recently identiﬁed
pharmacological agents that modulate MAC are of special interest
[23,32,74]. Also, our recent ﬁndings that MAC opening is linked to a
bystander effect is intriguing but is still a relatively unexplored area of
potential therapeutics [80]. Important questions remain about the
function and interplay amongst the Bcl-2 family of proteins and the
use of pharmacological compounds can be useful in elucidating their
answers. For example, in the recently described “priming for death”
mechanism, BH3 mimetics, like ABT-737, interfere with the interac-
tion of Bcl-2 with BH3-only or pro-apoptotic effector proteins in
presence of an apoptotic stimulus (Fig. 2). Thus, the combined action
of apoptosis inducers and BH3 mimetics would lead to MAC
formation, followed by cytochrome c release and cell death. In this
scenario, what is the mechanism of MAC formation? Do BH3-only
proteins directly activate Bax upon action by BH3 mimetics? Do BH3
mimetics also displace Bcl-2 from Bax? Also of intense interest is the
deﬁnition of the molecular identity of MAC, which undoubtedly will
require a proteomic approach to be fulﬁlled. In summary, a great deal
of information establishes MAC as a pivotal player in a deadly plot
with Bcl-2 members, which also provides clues for selective
therapeutic strategies for the treatment of cancer and degenerative
diseases.
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